Pia Paffenholz1, Tim Nestler2, Yasmine Maatoug3, Melanie von Brandenstein3, Barbara Köditz3, David Pfister3, Axel Heidenreich3,4. 1. Klinik für Urologie, Uro-Onkologie, spezielle urologische und roboter-assistierte Chirurgie, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland. pia.paffenholz@uk-koeln.de. 2. Department of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Deutschland. 3. Klinik für Urologie, Uro-Onkologie, spezielle urologische und roboter-assistierte Chirurgie, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland. 4. Department of Urology, Medical University Vienna, Vienna, Österreich.
Abstract
BACKGROUND: The prognostic classification system of the International Germ Cell Cancer Cooperative Group (IGCCCG) for testicular germ cell tumors is based on the histological subtype, location of the primary tumor, extent of metastatic spread and prechemotherapy tumor marker serum concentrations. OBJECTIVES: In this study, we aim to identify whether the use of preorchiectomy instead of prechemotherapy tumor marker serum concentration has an impact on IGCCCG risk group assignment. MATERIALS AND METHODS: We performed a retrospective analysis including 135 patients with metastasized testicular germ cell tumors. Analysis of the clinical information with a focus on the tumor marker serum concentration preorchiectomy and prechemotherapy was performed, thus leading to the grouping of patients according to IGCCCG risk group assignment. RESULTS: Using preorchiectomy instead of prechemotherapy tumor markers led to an incorrect IGCCCG risk group classification in 8% (11/135) of all patients, and consequently to a non-guideline concordant treatment. Up-staging was observed in 8 of 11 patients, representing 6% (8/135) of the total patient cohort. Three of the 11 misclassified patients showed a down-staging and thus describe 2% (3/135) of the total patient cohort. CONCLUSIONS: Using preorchiectomy tumor markers instead of prechemotherapy serum concentration might lead to an incorrect IGCCCG risk group assignment as well as non-guideline concordant treatment. Consequently, prechemotherapy tumor marker serum concentration should be applied for guideline concordant staging of patients.
BACKGROUND: The prognostic classification system of the International Germ Cell Cancer Cooperative Group (IGCCCG) for testicular germ cell tumors is based on the histological subtype, location of the primary tumor, extent of metastatic spread and prechemotherapy tumor marker serum concentrations. OBJECTIVES: In this study, we aim to identify whether the use of preorchiectomy instead of prechemotherapy tumor marker serum concentration has an impact on IGCCCG risk group assignment. MATERIALS AND METHODS: We performed a retrospective analysis including 135 patients with metastasized testicular germ cell tumors. Analysis of the clinical information with a focus on the tumor marker serum concentration preorchiectomy and prechemotherapy was performed, thus leading to the grouping of patients according to IGCCCG risk group assignment. RESULTS: Using preorchiectomy instead of prechemotherapy tumor markers led to an incorrect IGCCCG risk group classification in 8% (11/135) of all patients, and consequently to a non-guideline concordant treatment. Up-staging was observed in 8 of 11 patients, representing 6% (8/135) of the total patient cohort. Three of the 11 misclassified patients showed a down-staging and thus describe 2% (3/135) of the total patient cohort. CONCLUSIONS: Using preorchiectomy tumor markers instead of prechemotherapy serum concentration might lead to an incorrect IGCCCG risk group assignment as well as non-guideline concordant treatment. Consequently, prechemotherapy tumor marker serum concentration should be applied for guideline concordant staging of patients.
Authors: Robert D Frisina; Heather E Wheeler; Sophie D Fossa; Sarah L Kerns; Chunkit Fung; Howard D Sesso; Patrick O Monahan; Darren R Feldman; Robert Hamilton; David J Vaughn; Clair J Beard; Amy Budnick; Eileen M Johnson; Shirin Ardeshir-Rouhani-Fard; Lawrence H Einhorn; Steven E Lipshultz; M Eileen Dolan; Lois B Travis Journal: J Clin Oncol Date: 2016-06-27 Impact factor: 44.544
Authors: Janine Nuver; Andries J Smit; Jan van der Meer; Maarten P van den Berg; Winette T A van der Graaf; Martin T Meinardi; Dirk Th Sleijfer; Harald J Hoekstra; Anne I van Gessel; Arie M van Roon; Jourik A Gietema Journal: J Clin Oncol Date: 2005-11-21 Impact factor: 44.544
Authors: Christian Daniel Fankhauser; Travis A Gerke; Lisa Roth; Sophia Sander; Nico Christian Grossmann; Benedikt Kranzbühler; Daniel Eberli; Tullio Sulser; Joerg Beyer; Thomas Hermanns Journal: J Cancer Res Clin Oncol Date: 2019-01-14 Impact factor: 4.553
Authors: Kevin M Wymer; Shane M Pearce; Kelly T Harris; Phillip M Pierorazio; Siamak Daneshmand; Scott E Eggener Journal: J Urol Date: 2016-09-20 Impact factor: 7.450
Authors: Sarah L Kerns; Chunkit Fung; Patrick O Monahan; Shirin Ardeshir-Rouhani-Fard; Mohammad I Abu Zaid; AnnaLynn M Williams; Timothy E Stump; Howard D Sesso; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair Beard; Robert A Huddart; Jeri Kim; Christian Kollmannsberger; Deepak M Sahasrabudhe; Ryan Cook; Sophie D Fossa; Lawrence H Einhorn; Lois B Travis Journal: J Clin Oncol Date: 2018-04-04 Impact factor: 44.544
Authors: Arlo Radtke; Finja Hennig; Raphael Ikogho; Johannes Hammel; Petra Anheuser; Christian Wülfing; Gazanfer Belge; Klaus-Peter Dieckmann Journal: Urol Int Date: 2018-04-26 Impact factor: 2.089
Authors: Pia Paffenholz; Isabel Maria Heidegger; Kathrin Kuhr; Sven Heiko Loosen; David Pfister; Axel Heidenreich Journal: Clin Genitourin Cancer Date: 2017-09-06 Impact factor: 2.872